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Background:
Hepatitis B vaccination during childhood is key to reduce the 
prevalence of Hepatitis B virus (HBV) infection. In Senegal, a
highly endemic country, the three-dose hepatitis B vaccine and 
the birth dose vaccine were introduced in the Expanded 
Programme on Immunization (EPI) in 2004 and 2016 
respectively. This study aimed to determine chronic HBV
infection prevalence, hepatitis B vaccination status and vaccine 
immunity among children in Senegal.
Methods:
A cross-sectional study including HBV screening was con-
ducted at home among children aged 6 months to 15 years (i.e.
born after the introduction of the HBV vaccine in the EPI) in 
the rural zone of Niakhar. Dried Blood Spot (DBS) samples 
were collected for the detection of HBsAg, anti-HBc Ab and 
anti-HBs Ab using chemoluminescence. Vaccination status was 
assessed using information on vaccination cards. Detectable 
vaccine immunity was defined with an adjusted DBS threshold 
of DOI0.36 IU/mL (corresponding to 10 IU/mL in venous 
blood sampling).
Results:
Between October and December 2018, 455 children were 
enrolled. Preliminary results show that 7/455 (1.5%) had been
in contact with HBV (positive anti-HBc Ab) and 5/455 (1.1%) 
had chronic HBV infection (positive HBsAg).
Only 161/455 (35.4%) children had a vaccination card available.
Among those, 150/161 (93.2%) received at least 3 doses of 
hepatitis B vaccine, of which 83/150 (55.3%) had detectable 
vaccine immunity. The proportion of children with detectable
vaccine immunity was significantly higher in children <5 years 
than in children aged 5-9 and 10-15 (72.3% versus 47.3%,
p = 0.006 and 72.3% versus 14.3%, p < 0.001).
Conclusions:
Preliminary results suggest a low prevalence of HBV chronic 
infection among children born after the introduction of HBV 
vaccination in Senegal. However, detectable vaccine immunity 
rapidly decreases with age among vaccinated children,
signalling a need for further studies on the immune response
to HBV vaccination in this context.
Key messages:
 HBV chronic infection is low among children born after the
introduction of HBV vaccination in Senegal.
 Further studies on the immune response to HBV vaccina-
tion in this context are needed.
